Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

J. Bedke; L. Albiges; U. Capitanio; R. H. Giles; M. Hora; T. B. Lam; B. Ljungberg; L. Marconi; T. Klatte; Alessandro VOLPE; Y. Abu-Ghanem; S. Dabestani; S. Fernandez-Pello; F. Hofmann; T. Kuusk; R. Tahbaz; T. Powles; A. Bex

doi:10.1016/j.eururo.2020.12.005

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

J. Bedke, L. Albiges, U. Capitanio, R. H. Giles, M. Hora, T. B. Lam, B. Ljungberg, L. Marconi, T. Klatte, Alessandro VOLPE, Y. Abu-Ghanem, S. Dabestani, S. Fernandez-Pello, F. Hofmann, T. Kuusk, R. Tahbaz, T. Powles, A. Bex

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Longer follow-up data and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. A recent update of Keynote-426 demonstrated an ongoing overall survival benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a progression-free survival benefit seen across all International Metastatic RCC Database Consortium (IMDC) subgroups. The RCC Guidelines Panel continues to recommend this combination across IMDC risk groups in advanced first-line RCC.

Lingua originale	Inglese
pagine (da-a)	339-342
Numero di pagine	4
Rivista	European Urology
Volume	79
Numero di pubblicazione	3
DOI	https://doi.org/10.1016/j.eururo.2020.12.005
Stato di pubblicazione	Pubblicato - 2021

Keywords

Cabozantinib
Clear cell
First line
Nivolumab
Renal cell carcinoma
Systemic therapy
Treatment-naïve

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.eururo.2020.12.005

https://hdl.handle.net/11579/128309

Altri file e collegamenti

handle

Fingerprint

Entra nei temi di ricerca di 'Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma'. Insieme formano una fingerprint unica.

Cita questo

Bedke, J., Albiges, L., Capitanio, U., Giles, R. H., Hora, M., Lam, T. B., Ljungberg, B., Marconi, L., Klatte, T., VOLPE, A., Abu-Ghanem, Y., Dabestani, S., Fernandez-Pello, S., Hofmann, F., Kuusk, T., Tahbaz, R., Powles, T., & Bex, A. (2021). Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. European Urology, 79(3), 339-342. https://doi.org/10.1016/j.eururo.2020.12.005

@article{cf2daf34eb44432eaa12531095c1088b,

title = "Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-na{\"i}ve Metastatic Clear-Cell Renal Cell Carcinoma",

abstract = "Longer follow-up data and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. A recent update of Keynote-426 demonstrated an ongoing overall survival benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a progression-free survival benefit seen across all International Metastatic RCC Database Consortium (IMDC) subgroups. The RCC Guidelines Panel continues to recommend this combination across IMDC risk groups in advanced first-line RCC.",

keywords = "Cabozantinib, Clear cell, First line, Nivolumab, Renal cell carcinoma, Systemic therapy, Treatment-na{\"i}ve, Cabozantinib, Clear cell, First line, Nivolumab, Renal cell carcinoma, Systemic therapy, Treatment-na{\"i}ve",

author = "J. Bedke and L. Albiges and U. Capitanio and Giles, \{R. H.\} and M. Hora and Lam, \{T. B.\} and B. Ljungberg and L. Marconi and T. Klatte and Alessandro VOLPE and Y. Abu-Ghanem and S. Dabestani and S. Fernandez-Pello and F. Hofmann and T. Kuusk and R. Tahbaz and T. Powles and A. Bex",

note = "Publisher Copyright: {\textcopyright} 2020 European Association of Urology",

year = "2021",

doi = "10.1016/j.eururo.2020.12.005",

language = "English",

volume = "79",

pages = "339--342",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "3",

}

Bedke, J, Albiges, L, Capitanio, U, Giles, RH, Hora, M, Lam, TB, Ljungberg, B, Marconi, L, Klatte, T, VOLPE, A, Abu-Ghanem, Y, Dabestani, S, Fernandez-Pello, S, Hofmann, F, Kuusk, T, Tahbaz, R, Powles, T & Bex, A 2021, 'Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma', European Urology, vol. 79, n. 3, pagg. 339-342. https://doi.org/10.1016/j.eururo.2020.12.005

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. / Bedke, J.; Albiges, L.; Capitanio, U. et al.
In: European Urology, Vol. 79, N. 3, 2021, pag. 339-342.

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

TY - JOUR

T1 - Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

AU - Bedke, J.

AU - Albiges, L.

AU - Capitanio, U.

AU - Giles, R. H.

AU - Hora, M.

AU - Lam, T. B.

AU - Ljungberg, B.

AU - Marconi, L.

AU - Klatte, T.

AU - VOLPE, Alessandro

AU - Abu-Ghanem, Y.

AU - Dabestani, S.

AU - Fernandez-Pello, S.

AU - Hofmann, F.

AU - Kuusk, T.

AU - Tahbaz, R.

AU - Powles, T.

AU - Bex, A.

PY - 2021

Y1 - 2021

N2 - Longer follow-up data and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. A recent update of Keynote-426 demonstrated an ongoing overall survival benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a progression-free survival benefit seen across all International Metastatic RCC Database Consortium (IMDC) subgroups. The RCC Guidelines Panel continues to recommend this combination across IMDC risk groups in advanced first-line RCC.

AB - Longer follow-up data and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. A recent update of Keynote-426 demonstrated an ongoing overall survival benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a progression-free survival benefit seen across all International Metastatic RCC Database Consortium (IMDC) subgroups. The RCC Guidelines Panel continues to recommend this combination across IMDC risk groups in advanced first-line RCC.

KW - Cabozantinib

KW - Clear cell

KW - First line

KW - Nivolumab

KW - Renal cell carcinoma

KW - Systemic therapy

KW - Treatment-naïve

KW - Cabozantinib

KW - Clear cell

KW - First line

KW - Nivolumab

KW - Renal cell carcinoma

KW - Systemic therapy

KW - Treatment-naïve

UR - https://iris.uniupo.it/handle/11579/128309

U2 - 10.1016/j.eururo.2020.12.005

DO - 10.1016/j.eururo.2020.12.005

M3 - Article

SN - 0302-2838

VL - 79

SP - 339

EP - 342

JO - European Urology

JF - European Urology

IS - 3

ER -